Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles

Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01791751

Acronym

CLOFA

Enrollment

Registered

2013-02-15

Start date

2012-06-30

Completion date

2013-02-28

Last updated

2013-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Infertility

Brief summary

The purpose of this study is to evaluate the effect on LH levels of the 5-day CC administration during luteal phase in oocyte donors, to investigate whether the CC corrects the suppressed LH levels in the luteal phase and whether it prolongs the luteal phase in the agonist triggered antagonist cycles.

Interventions

DRUGClomifene Citrate

Clomiphene citrate 100 mg daily for 5 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Oocyte donors * 18-35 years old * BMI 18-29 Kg/m2 * Normal basal hormonal levels * No contraceptive pill

Exclusion criteria

* Polycystic ovarian syndrome (PCOS) * Previous participation in the study

Design outcomes

Primary

Measure	Time frame
LH Levels (IU)	Luteal phase (up to 2 weeks)

Secondary

Measure	Time frame
Endometrial development (Noyes criteria)	Luteal phase (1 day)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026